{"id":7606,"date":"2025-12-06T08:00:35","date_gmt":"2025-12-06T07:00:35","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=congress-resource&#038;p=7606"},"modified":"2025-12-08T13:52:01","modified_gmt":"2025-12-08T12:52:01","slug":"incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib","status":"publish","type":"congress-resource","link":"https:\/\/beonemedaffairs.com\/us\/congress-resource\/7606\/incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib\/","title":{"rendered":"Incidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib"},"content":{"rendered":"","protected":false},"template":"","post-tag":[760,704,804,762],"class_list":["post-7606","congress-resource","type-congress-resource","status-publish","hentry","post-tag-american-society-of-hematology","post-tag-ash","post-tag-heor","post-tag-rwe","congress_resource_type-abstract","content_type-reading"],"acf":{"congress_resource_url_override":"ash-2025","congress":6819,"category":242,"prioritization":0,"key_data_presentation":true,"key_data_presentation_only":true,"key_data_presentation_prioritization":40,"tags":[704,760,804,762],"visible_tags":[704],"content-type":246,"summary":"","text_app":"<em>\r\nThe contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","text":"<em>\r\nThe contents of the presentations above are designed for educational and scientific exchange purposes and are not promotional. They may contain information on investigational products or investigational uses of approved products. No conclusions regarding safety and\/or efficacy for such investigational products or uses may be made.<\/em>","table_heading":"","table":null,"faq_heading":"FREQUENTLY ASKED QUESTIONS","faq":null,"button_alt_link":"","no_post_image_preview":true,"download_file_reading":"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_ABSTRACT_incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib.pdf","display_file_reading":null,"download_file_slidekit":null,"display_file_slidekit":null,"3qsdn":"","webcast":"","vimeo_url":"","videolange":null,"fliphtml_link":"","use_pdf_instead_of_fliphtml":false,"congress_resource_abstract_link":"","congress_resource_cta_label":"","congress_resource_cta_link":"","authors":[7346],"field_page_schema_override":[{"field_page_schema_override_type":"PresentationDigitalDocument","field_page_schema_override_data":"{\r\n  \"@type\": \"PresentationDigitalDocument\",\r\n  \"name\": \"Incidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib \u2013 BeOne Medical Affairs | US\", \r\n  \"description\": \"See the ASH 2025 abstract on the incidence of cardiac-related deaths in patients \u226565 years treated with ibrutinib in B-cell malignancies by Ryan Jacobs et al.\",  \r\n  \"image\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib.png\",\r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib\/\",  \r\n  \"associatedMedia\": {\r\n    \"@type\": \"MediaObject\",\r\n    \"contentUrl\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/12\/ASH2025_ABSTRACT_incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib.pdf\",\r\n    \"encodingFormat\": \"application\/pdf\"\r\n  },\r\n  \"datePublished\": \"2025-12-06\",  \r\n  \"keywords\": [\"ibrutinib cardiac mortality elderly patients\", \"ibrutinib cardiovascular toxicity risk older adults\", \"risk factors cardiovascular death ibrutinib therapy\", \"ibrutinib cardiac risk\", \"cardiac death ibrutinib\", \"ibrutinib heart failure risk\"], \r\n  \"author\": {\r\n    \"@type\": \"Person\",\r\n    \"name\": \"Ryan Jacobs, MD\"\r\n  },\r\n  \"publisher\": {\r\n    \"@type\": \"Organization\",\r\n    \"name\": \"BeOne Medicines\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/\"\r\n  },\r\n  \"about\": {\r\n    \"@type\": \"MedicalStudy\",\r\n    \"name\": \"Incidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib\",  \r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib\/\"\r\n  }\r\n}"},{"field_page_schema_override_type":"MedicalWebPage","field_page_schema_override_data":"{\r\n  \"@type\": \"MedicalWebPage\",   \r\n  \"name\": \"Incidence of cardiac-related deaths among patients aged \u226565 years with B-cell malignancies treated with ibrutinib \u2013 BeOne Medical Affairs | US\",   \r\n  \"description\": \"See the ASH 2025 abstract on the incidence of cardiac-related deaths in patients \u226565 years treated with ibrutinib in B-cell malignancies by Ryan Jacobs et al.\",  \r\n  \"url\": \"https:\/\/beonemedaffairs.com\/us\/congress-resources\/ash-2025\/incidence-of-cardiac-related-deaths-65-years-and-older-with-b-cell-malignancies-treated-with-ibrutinib\/\", \r\n  \"inLanguage\": \"en-US\",\r\n  \"@logo\": {\r\n    \"@type\": \"ImageObject\",\r\n    \"url\": \"https:\/\/beonemedaffairs.com\/us\/wp-content\/uploads\/sites\/11\/2025\/03\/BGI2404-BeOne-Primary-Logo-RGB-M04-V01-2.svg\"\r\n  }\r\n}"}]},"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource\/7606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress-resource"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/congress-resource"}],"acf:post":[{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/authors\/7346"},{"embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress\/6819"}],"acf:term":[{"embeddable":true,"taxonomy":"content_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/content_type\/246"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/762"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/804"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/760"},{"embeddable":true,"taxonomy":"post-tag","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag\/704"},{"embeddable":true,"taxonomy":"congress_resource_type","href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/congress_resource_type\/242"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=7606"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=7606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}